Anti-SART1 monoclonal antibody, clone FQS25674(C)

Objective: To describe institutional clinical policies and individual provider opinions regarding aneuploid embryo transfer (aET). Design: A survey about clinical policies was electronically sent to Society for Assisted Reproductive Technology (SART) member laboratory directors, and a separate survey about personal opinions was electronically sent to all SART members. Setting: Not applicable. Patients: Patients pursuing preimplantation genetic testing for aneuploidy (PGT-A). Intervention: Not applicable. Main Outcome Measures: Current clinical policies about aET were described. Individual provider opinions about aET in the context of speci fi c aneuploidies and mosaicism were also described. Results: A total of 48 laboratory directors and 212 individual providers responded to their respective surveys. Twelve (25%) clinics report that they do not have a policy regarding aET, but clinics performing PGT-A in 100 cycles per year were more likely to have a policy. Half of the individual providers agree that an embryo with trisomy 21 should be available for aET, but most disagreed with aET of embryos with other aneuploidies and most were either unsure about or unwilling to transfer embryos with mosaicism. Those who worked in primarily patient -facing roles held more agreeable opinions regarding aET. Conclusion: There is no consensus regarding ideal clinical policies for aET. The wide range of current clinical practices and individual provider opinions regarding under what circumstances, if any, aET should be available to patients indicates that this is a divisive issue among ART providers, and there is a clear need for speci fi c professional guidelines to address this issue. (Fertil Steril (R) 2020;114:110-7. (C) 2020 by American Society for Reproductive Medicine.)

Objective: To assess in vitro fertilization (IVF) and pregnancy outcomes in patients having their first frozen embryo transfer (FET) after a freeze-all cycle versus similar patients having their first fresh embryo transfer (ET). Design: Retrospective cohort study. Setting: None. Patient(s): Registry data on 82,935 patient cycles from the Society for Assisted Reproductive Technology (SART). Intervention(s): All first fresh autologous IVF cycles were analyzed and compared to first FET cycles after a freeze-all first IVF stimulation. The cycles were subdivided into cohorts based upon the number of oocytes retrieved (OR): 1-5 (low), 6-14 (intermediate), and 15+ (high responders). Univariate analyses were performed on cycle characteristics, and multivariable regression analyses were performed on outcome data. Main Outcome Measure(s): Clinical pregnancy rate (CPR) and live-birth rate (LBR). Results: Of the 82,935 cycles analyzed, 69,102 patients had their first fresh transfer, and 13,833 had a first FET. High responders were found to have a higher CPR and LBR in the FET cycles compared with the fresh ET cycles (61.5 vs. 57.4%; 52.0 vs. 48.9%). In intermediate responders, both CPR and LBR were higher after fresh ET compared with FET (49.6% vs. 44.2%; 41.2 vs. 35.3%). Similarly, in low responders, CPR and LBR were higher after fresh compared with FET (33.2% vs. 15.9%; 25.9% vs. 11.5%). Conclusion(s): A freeze-all strategy is beneficial in high responders but not in intermediate or low responders, thus refuting the idea that freeze-all cycles are preferable for all patients. (C) 2018 by American Society for Reproductive Medicine.